Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Bought by Principal Financial Group Inc.

Principal Financial Group Inc. raised its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 4.0% during the fourth quarter, Holdings Channel.com reports. The firm owned 296,732 shares of the specialty pharmaceutical company’s stock after purchasing an additional 11,321 shares during the period. Principal Financial Group Inc.’s holdings in Supernus Pharmaceuticals were worth $10,730,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Supernus Pharmaceuticals by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company’s stock worth $61,000 after purchasing an additional 352 shares during the last quarter. Newbridge Financial Services Group Inc. purchased a new position in Supernus Pharmaceuticals during the fourth quarter worth about $72,000. KBC Group NV increased its position in shares of Supernus Pharmaceuticals by 53.1% during the fourth quarter. KBC Group NV now owns 2,679 shares of the specialty pharmaceutical company’s stock valued at $97,000 after acquiring an additional 929 shares during the last quarter. Kennebec Savings Bank purchased a new stake in shares of Supernus Pharmaceuticals in the 3rd quarter valued at approximately $103,000. Finally, Janney Montgomery Scott LLC acquired a new position in shares of Supernus Pharmaceuticals in the 4th quarter worth approximately $211,000.

Supernus Pharmaceuticals Price Performance

Shares of NASDAQ:SUPN opened at $32.06 on Friday. The firm has a market capitalization of $1.77 billion, a PE ratio of 29.96 and a beta of 0.90. Supernus Pharmaceuticals, Inc. has a 1 year low of $25.53 and a 1 year high of $40.28. The firm’s 50-day moving average is $37.12 and its two-hundred day moving average is $35.34.

Wall Street Analyst Weigh In

SUPN has been the subject of several research reports. StockNews.com downgraded shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday. Cantor Fitzgerald restated a “neutral” rating and set a $36.00 price target on shares of Supernus Pharmaceuticals in a research report on Wednesday.

Insider Activity at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, SVP Jonathan Rubin sold 927 shares of the firm’s stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the transaction, the senior vice president now owns 7,853 shares of the company’s stock, valued at $307,444.95. This trade represents a 10.56 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, VP Padmanabh P. Bhatt sold 9,477 shares of the company’s stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total value of $376,236.90. Following the sale, the vice president now directly owns 10,149 shares in the company, valued at $402,915.30. This represents a 48.29 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 11,104 shares of company stock worth $440,263. Corporate insiders own 9.30% of the company’s stock.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.